Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT02918032
Recruiting Observational

International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases

NCT02918032 · tracked via the Priya Life Science Italy tracker
Sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase
Observational
Started
2014-01
Last updated
2026-02-05

Condition(s) studied

Neutral Lipid Storage Disease

Study summary

This study aims to understand the state of onset of NLSD(neutral lipid storage disease) / TGCV(triglyceride deposit cardiovasculopathy) worldwide, background information of affected patients, and natural history of the disease, as well as exploring the prognostic factors and assessing the efficacy of disease-specific treatment.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients who are diagnosed with NLSD / TGCV Exclusion Criteria: * None

Primary outcome measure(s)

  • Period from the diagnosis of NLSD / TGCV to death from any cause — 5 years
    This is the period from the date of diagnosis of NLSD / TGCV to the date of death from any cause. The last date of confirmation of survival will be used as the cut-off date for living patients and patients who are lost to follow-up.

Trial sites (15)

FacilityCityRegionStatus
Stanford University Stanford California Recruiting
Columbia University New York New York Recruiting
University of Graz Graz Styria Recruiting
Peking University First Hospital Beijing Beijing Municipality Recruiting
Pitié-Salpêtrière Hospital Paris Paris Recruiting
Ludwig-Maximilians University Munich Bavaria Recruiting
Sapienza University of Rome Rome Lazio Recruiting
A.C.O. San Filippo Neri Hospital Rome Lazio Recruiting
Catholic University Milan Lombardy Recruiting
University of Padova Padova Veneto Recruiting
Graduate School of Osaka University Suita Osaka Recruiting
National Center of Neurology and Psychiatry Kodaira Tokyo Recruiting
Maastricht University Maastricht Limburg Recruiting
Harefield Hospital Harefield London Recruiting
New Castle University Newcastle upon Tyne Tyne and Wear Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02918032 on ClinicalTrials.gov ↗ ← All trials in Italy